According to a recent market study published by Growth Market Reports (GMR), titled, “Global Orally Disintegrating Tablets Market by drug class, disease indication, and by Region: Size, Share, Trends and Opportunity Analysis, 2017-2027″, the market was valued at USD 11,988 Million in 2019 and is expected to grow at a healthy growth rate of 10.18% by the year 2027. The ODT market is anticipated to grow significantly during forecast period. ODTs are gaining tremendous importance as compared to other dosage form owing to their benefits. ODTs have better stability, easier production process, convenient packing size, bioavailability, rapid onset of action and high patient compatibility.
Request a free sample copy: https://growthmarketreports.com/request-sample/153
Global orally disintegrating tablets market has been fragmented based on drug class, disease indications, and by regions. In terms of drug class, the global ODT market is categorized as antipsychotics, anti-epileptics, CNS stimulants, anxiolytics, antiparkinsonian drugs, anti-hypertensive, NSAIDS, anti-allergy drugs, proton pump inhibitors, vaccine ODT and others. Based on disease indication, the market is classified as central nervous system (CNS) diseases, gastrointestinal (GI) diseases, cardiovascular (CVS) diseases, allergy and others. By region ODT market is segmented into North America, Europe, Asia Pacific, Latin America, and Middle East & Africa (MEA). North America region is further bifurcated into countries such as the U.S., and Canada. The Latin America region is further segmented into Brazil, Mexico, and Rest of Latin America, the Asia Pacific is further segmented into, China, Japan, South Korea, Australia, Southeast Asia, and Rest of Asia Pacific. The European region is further categorized into Germany, France, Italy, the U.K., Spain, Russia, and the Rest of Europe, and the MEA region is further divided into Saudi Arabia, South Africa, UAE, and the Rest of MEA.
The effect of COVID-19 pandemic situation has led to the closure of several non-essential businesses reducing the demand for industrial goods in the world, which in turn, is affecting several industries worldwide. On the other hand, the COVID-19 pandemic is encouraging production activities across orally dissolving tablets manufacturing units worldwide, the demand for ODTs has surged throughout the pandemic. As people are inclining towards ODTs during the lockdown period for their health benefits. The global supply chain has slowed down due to restrictions on national borders. Regarding the ODTs market as demand has been growing at normal growth rate during pandemic situation. Additionally, the ODT production has grown and the market is expected to witness significant growth post COVID.
For More Information: https://growthmarketreports.com/enquiry-before-buying/153
As per GMR industry analyst Vidya Jadhav, “The rising old population, and increasing prevalence of diseases and growing number of mentally disabled people many countries are anticipated to drive the growth of ODT market significantly. Moreover, the Emerging Demand from Developing Countries and diseases such as coronavirus (COVID-19) are anticipated to create lucrative opportunity during forecast period.”
Buy Full Report at https://growthmarketreports.com/report/orally-disintegrating-tablets-marketglobal-industry-analysis
Report Metric |
Details |
Market Value in 2019 |
USD 11,988 Million |
Market Growth Rate (from 2021 to 2027) |
10.18% |
Historical Data |
2017 & 2018 |
Base Year |
2019 |
Forecast Period |
2020 – 2027 |
Market Segments |
Drug Class, Disease Indication |
Regional Scope |
North America, Europe, Latin America, Asia Pacific, Middle East & Africa (MEA) |
Country Scope |
U.S., Canada, Brazil, Mexico, Rest of Latin America, China, Japan, South Korea, India, Australia, Southeast Asia, Rest of Asia Pacific, Germany, France, Italy, U.K., Spain, Russia, Rest of Europe, Saudi Arabia, South Africa, UAE and Rest of MEA. |
Key Companies Profiled |
Alkem Labs, Amneal Pharmaceuticals LLC, Apotex Inc., Aurobindo Pharma, Bausch Health Companies Inc., Eli Lilly and Company, GlaxoSmithKline plc, Glenmark Pharmaceuticals Limited, Johnson & Johnson Services, Inc., Merck & Co., Inc., Novartis AG, Sun Pharmaceutical Industries Ltd., Takeda Pharmaceutical Company Limited, Teva Pharmaceutical Industries Ltd, Viatris Inc. (Mylan N.V. and Pfizer’s Upjohn) |
Customization Scope |
Report customization available on request |
Pricing and Purchase Options |
Avail tailor-made purchase options to meet your research requirements. |
Request a free sample copy: https://growthmarketreports.com/request-sample/153
About Us:
Our reports are more than just research reports to us. They are tools that enable us to maintain long-term relationships with our clients whom we honor and cherish. Our client’s business growth is integral for not only them but also us. This is what differentiates us from other market research companies.
At GMR, we provide our expertise and guideline for success. Our team of efficient and experienced researchers and consultants provide progressive market intelligence reports that are accurate, authentic, and in-depth. This empowers the clients to make well-informed decisions.
Moreover, we offer market intelligence studies, ensuring relevant and fact-based research across a range of industries including chemicals and materials, energy, automobile, healthcare, consumer goods, and technology. Our deep understanding of many business environments across industries such as those mentioned above allows us to deliver tailor-made reports.